Universal 'Off-the-Shelf' cell therapy trial launches for aggressive leukemia
NCT ID NCT07432100
Summary
This early-phase study is testing a new type of 'universal' CAR-T cell therapy for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. The therapy uses donor immune cells engineered to target a protein called CLL1 found on most AML cancer cells. Researchers aim to see if this 'off-the-shelf' approach is safe, can reduce cancer in the bone marrow, and help patients live longer without their disease getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.